U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H20N4
Molecular Weight 328.4103
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERDEMETAN

SMILES

C(CC1=CNC2=C1C=CC=C2)NC3=CC=C(NC4=CC=NC=C4)C=C3

InChI

InChIKey=CEGSUKYESLWKJP-UHFFFAOYSA-N
InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)

HIDE SMILES / InChI

Molecular Formula C21H20N4
Molecular Weight 328.4103
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.eurodiagnostico.com/media/pdf/JNJ%2026854165%20(Serdemetan).pdf http://adisinsight.springer.com/drugs/800014298

JNJ-26854165 (Serdemetan), a novel tryptamine derivative, was developed as an activator of p53, and its initially proposed mechanism of action involved preventing the association of HDM2 with the proteasome and thereby stabilizing HDM2 substrates such as p53. Consistent with this proposed mechanism, Serdemetan induced apoptosis in acute myeloid and lymphoid leukemia cell lines and in primary acute leukemia isolates. Serdemetan is currently being evaluated in Phase I clinical trials in patients with non-small cell lung cancer; prostate cancer; solid tumours.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes.
2013
The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.
2013 Sep
Patents

Sample Use Guides

The maximum tolerated dose (MTD) of serdemetan was determined to be 350 mg once daily.
Route of Administration: Oral
Serdemetan induced a dose-dependent inhibition of proliferation in both wild-type (wt) and mutant (mut) p53 cell lines, with IC50 values from 0.25 to 3 uM/L, in association with an S phase cell cycle arrest.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:15:33 GMT 2023
Edited
by admin
on Fri Dec 15 17:15:33 GMT 2023
Record UNII
ID6YB4W3V8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERDEMETAN
INN   WHO-DD  
INN  
Official Name English
JNJ-26854165
Code English
Serdemetan [WHO-DD]
Common Name English
N-(2-(1H-INDOL-3-YL)ETHYL)-N'-(PYRIDIN-4-YL)BENZENE-1,4-DIAMINE
Systematic Name English
serdemetan [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129839
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
Code System Code Type Description
PUBCHEM
11609586
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
DRUG BANK
DB12027
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
NCI_THESAURUS
C77904
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
FDA UNII
ID6YB4W3V8
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
CAS
881202-45-5
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
EPA CompTox
DTXSID30236830
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
INN
9161
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
SMS_ID
100000175232
Created by admin on Fri Dec 15 17:15:33 GMT 2023 , Edited by admin on Fri Dec 15 17:15:33 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDING
Related Record Type Details
ACTIVE MOIETY